Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zhang, Yuannv ^a   Qiu, Zhaoping ^a   Wei, Lin ^a   Tang, Ruqi ^a   Lian, Baofeng ^b   Zhao, Yingjun ^a   He, Xianghuo ^a   Xie, Lu ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADCY GENE; ALB GENE; APOPTOSIS; ARID1A GENE; ARID2 GENE; ARTICLE; AXIN1 GENE; CARCINOGENESIS; CELL PROLIFERATION; CIRCADIAN RELATED PATHWAY; COL11A1 GENE; CONTROLLED STUDY; CTNNB1 GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GNAL GENE; GPR98 GENE; HUMAN; LIVER CELL CARCINOMA; LRP1B GENE; METABOLIC RELATED PATHWAY; MLL3 GENE; NEURAL SIGNALING RELATED PATHWAY; ONCOGENE; PCLO GENE; PROLIFERATION AND APOPTOSIS RELATED PATHWAY; RPS6KA3 GENE; SIGNAL TRANSDUCTION; TP53 GENE; TUMOR MICROENVIRONMENT; TUMOR MICROENVIRONMENT RELATED PATHWAY; USH2A GENE; GENETICS; INFORMATION PROCESSING; LIVER TUMOR; MUTATION; NUCLEIC ACID DATABASE; NUCLEOTIDE SEQUENCE; TUMOR GENE;

CARCINOMA, HEPATOCELLULAR; DATABASES, NUCLEIC ACID; DATASETS AS TOPIC; DNA MUTATIONAL ANALYSIS; GENES, NEOPLASM; HUMANS; LIVER NEOPLASMS; MUTATION; SIGNAL TRANSDUCTION;

EID: 84903770490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100854     Document Type: Article

References (57)

1. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698.
2. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, et al. (2010) Cancer gene discovery in hepatocellular carcinoma. J Hepatol 52: 921-929.
3. Nault JC, Zucman-Rossi J (2014) Genetics of hepatocellular carcinoma: the next generation. J Hepatol 60: 224-226.
4. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
5. Huang J, Deng Q, Wang Q, Li KY, Dai JH, et al. (2012) Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 44: 1117-1121.
6. Li M, Zhao H, Zhang X, Wood LD, Anders RA, et al. (2012) Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43: 828-829.
7. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. (2012) Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44: 765-769.
8. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, et al. (2013) Cancer genome landscapes. Science 339: 1546-1558.
9. Ciriello G, Cerami E, Sander C, Schultz N (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22: 398-406.
10. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. (2010) International network of cancer genome projects. Nature 464: 993-998.
11. Kan Z, Zheng H, Liu X, Li S, Barber TD, et al. (2013) Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 23: 1422-1433.
12. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
13. TCGA-Consortium (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
14. Gasper G, Rahman M (2004) Basic hypergeometric series. Cambridge, UK; New York: Cambridge University Press. xxvi, 428 p.
15. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29: 4989-5005.
16. Ho M (2011) Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs 25: 275-284.
17. Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717.
18. Rydzanicz M, Wrzesinski T, Bluyssen HA, Wesoly J (2013) Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Lett 341: 111-126.
19. Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257.
20. Katoh M (2012) Function and cancer genomics of FAT family genes (review). Int J Oncol 41: 1913-1918.
21. Cefalu AB, Pirruccello JP, Noto D, Gabriel S, Valenti V, et al. (2013) A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 33: 2021-2025.
22. Prevarskaya N, Skryma R, Shuba Y (2011) Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 11: 609-618.
23. Yang JD, Nakamura I, Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 21: 35-43.
24. Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, et al. (2012) The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 40: 1733-1747.
25. Molloy NH, Read DE, Gorman AM (2011) Nerve growth factor in cancer cell death and survival. Cancers (Basel) 3: 510-530.
26. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
27. Sahar S, Sassone-Corsi P (2009) Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9: 886-896.
28. Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, et al. (2011) Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum Gene Ther 22: 1109-1119.
29. Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, et al. (2014) Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology 146: 222-232 e235.
30. Luedde T, Schwabe RF (2011) NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108-118.
31. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858. (Pubitemid 46094197)
32. Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46: 590-597. (Pubitemid 47344795)
33. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, et al. (2008) PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118: 683-694. (Pubitemid 351206557)
34. Seki E, Brenner DA, Karin M (2012) A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 143: 307-320.
35. Zhao P, Zhang W, Wang SJ, Yu XL, Tang J, et al. (2011) HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology 54: 2012-2024.
36. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, et al. (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29: 1192-1196. (Pubitemid 351964880)
37. Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, et al. (2012) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 56: 184-191.
38. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J (2003) PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 38: 1242-1249.
39. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, et al. (2004) Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 10: 4140-4149.
40. Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, et al. (2008) Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol 98: 190-196.
41. Chew V, Chen J, Lee D, Loh E, Lee J, et al. (2012) Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 61: 427-438.
42. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183. (Pubitemid 38337497)
43. Gong X, Wu R, Zhang Y, Zhao W, Cheng L, et al. (2010) Extracting consistent knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics 11: 76.
44. Anjum R, Blenis J (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9: 747-758.
45. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30. (Pubitemid 30047706)
46. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, et al. (2014) The Reactome pathway knowledgebase. Nucleic Acids Res 42: D472-477.
47. Zhang G, Liu T, Wang Z (2012) Downregulation of MAGI1 associates with poor prognosis of hepatocellular carcinoma. J Invest Surg 25: 93-99.
48. Bai J, Zhou Y, Chen G, Zeng J, Ding J, et al. (2011) Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol 42: 375-383.
49. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, et al. (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30: 35-51.
50. Wang YH, Dong YY, Wang WM, Xie XY, Wang ZM, et al. (2013) Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kappaB pathways induced by paracrine cytokines. J Exp Clin Cancer Res 32: 51.
51. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y, et al. (2012) Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncol Rep 28: 874-882.
52. Ge C, Li Q, Wang L, Xu X (2013) The role of axon guidance factor semaphorin 6B in the invasion and metastasis of gastric cancer. J Int Med Res 41: 284-292.
53. Yang Y, Fu LM (2003) TSGDB: a database system for tumor suppressor genes. Bioinformatics 19: 2311-2312. (Pubitemid 37483988)
54. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900. (Pubitemid 35012462)
55. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
56. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, et al. (2010) Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 6: e1001025.
57. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodol), 57: 289-300.